Breast Cancer Research and Treatment **57**: 299, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 57

Abeloff MD 201
Allen BJ 285
Alonso DF 271
Aslani A 285
Auer G 245

Bal de Kier Joffé E 271
Bando E 221
Barth RJ Jr 291
Bianchi G 157
Bonilla F 237
Brodie A 183

Caduff R 215
Carretero L 237
Caruso R 277
Chao T-C 193
Chen M-F 193
Chen S-C 193
Cowan KH 277

Dalberg K 245
Denicoff A 277
Dickson RB 297
Dominguez G 237
Dorr FA 277

Eriksson E 245
España P 237

Farías EF 271
Flanders C 277
Fredriksson I 245
Fusek M 261

Garcia JM 237
Gazzanelli G 157
Gimbel M 183
Gomez DE 271
Gonzalez R 237
Goodman L 277
Gossard M 277
Grigoryev D 183
Guisti R 277

Hakama M 165
Heikkilä MM 165
Hochster H 201

Isomaa V 175

Johansson U 245

Kaiser M 277
Kanter L 245
Kucuk O 201

Levi JA 285
Liedberg A 245
Liu Y 183
Lo Y-F 193
Long BJ 183
Lu Q 183

Malatesta M 157
Mannello F 157
Merino M 277
Michigishi T 221
Miettinen M 175
Minato H 221
Miwa K 221
Mustonen M 175

Nakajima K 221
Navarro A 237
Noguchi M 221
Nonomura A 221
Noone MA 277

O'Shaughnessy JA 277

Pai L 277
Pandya KJ 201
Pavlakis N 285
Perez E 207
Poutanen M 175
Provencio M 237

Rutqvist LE 245

Saarenmaa IE 165
Salminen TM 165
Sandelin K 245
Sebastiani M 157
Silva JM 237
Skeel RT 201
Skilton G 271
Smith RC 285
Söderqvist G 175

Thorstensson S 245
Tonami N 221
Tsugawa K 221

Varga Z 215
Venzon D 277
Vetvicka V 261
Vetvickova J 261
Vihko P 175
Vihko R 175

Wakefield L 277
Wickman M 175

Yokoyama K 221

Zujewski J 277

Breast Cancer Research and Treatment **57**: 301-303, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 57

5-fluorouracil (5FU)
  phase II second-line cisplatin/5FU 201-206

adjuvant therapy
  abstracts 47-49
advocacy
  abstracts 45
age
  and likelihood of local recurrence after breast-conserving surgery 245-259
allelic losses
  of the PTEN region (10q23), correlated with markers of poor prognosis 237-243
anastrozole
  combined with antiestrogens in nude mouse model 183-192
angiogenesis
  abstracts 92-93
antiemetic therapy
  review of 5-HT_3 antagonists with breast cancer chemotherapy 207-214
antiestrogens
  abstracts 25,52-53
  tamoxifen, faslodex combined with aromatase inhibitors in nude mouse model 183-192
antigens and markers
  abstracts 94-95
apoptosis
  abstracts 93-94
  low in glycogen-rich breast cancers 215-219
aromatase inhibitors
  letrozole, anastrozole combined with antiestrogens in nude mouse model 183-192
axillary dissection
  complete, compared with sentinel lymph-adenectomy 221-229
axillary nodes
  abstracts 35-41

biomarkers
  see markers, prognostic factors
biopsy techniques
  abstracts 77
bone marrow micrometastases
  abstracts 119-121
bone metastases
  abstracts 91-92
breast cancer web site
  for scientific exchange — review 297-298
breast conservation
  abstracts 34,49-51
  biomarkers for local recurrence 245-259

cathepsin D
  blocking activation peptide of enzymatically inactive procathepsin D inhibits tumor growth 261-269
cell aggregation
  inhibited by vasopressin analogue desmopressin 271-275
cell biology
  abstracts 138-139
chemotherapy
  general — abstracts 29-30,84-91
  high dose with support — abstracts 65-67
  neoadjuvant — abstracts 67-70
  new drugs and formulations — abstracts 122-127
  phase II second-line cisplatin/5FU 201-206
  support regimens — abstracts 127
  weight gain with adjuvant CMF — increased fat mass 285-290
cisplatin
  phase II second-line cisplatin/5FU 201-206
color Doppler ultrasound
  incomplete differentiation of benign and malignant breast lesions 192-199
cost-effectiveness
  abstracts 105
cyst fluids
  source of PSA 157-163

DCIS
  abstracts 33-34,70-72
desmopressin
  inhibition of tumor cell aggregation and metastasis 271-275
detection
  abstracts 78
diagnosis
  color Doppler ultrasound — incomplete benign/malignant differentiation 192-199
diagnostic pathology
  abstract 79

diet and nutrition
abstracts 79
drug resistance
abstracts 55

EGFR
abstracts 26-27
endocrine therapy
abstracts 25,30-32,106-107
combination antiestrogen and aromatase inhibitor in nude mouse model 183-192
endocrinology
abstracts 53
epidemiology
abstracts 43-44
erbB-2
abstract 26
estrogen metabolism
17β-hydroxysteroid dehydrogenase isozymes and activities in normal breast 175-182
estrogen receptor
abstracts 28,95-97
exercise
abstract 92

familial breast cancer
abstracts 79-81
faslodex
combined with aromatase inhibitors in nude mouse model 183-192
fenretinide
tamoxifen/fenretinide therapy inactive in ER– or tam-failing tumors 277-283
fibrocystic breast disease
PSA from apocrine cells lining cysts 157-163

gene therapy
abstracts 54
genetic testing
abstracts 79-81
genetics
abstracts 133-134
glycogen-rich breast carcinomas
low-proliferation low-apoptosis cell kinetic profile 215-219
granisetron
review of 5-HT_3 antagonist antiemetics with breast cancer chemotherapy 207-214
growth factors and inhibitors
abstracts 113-116

Herceptin
abstracts 29
hereditary breast cancer
abstract 32
hormone replacement therapy
abstracts 30,132
hormone therapy
see endocrine therapy
hydroxysteroid dehydrogenases
17HSD isozymes and activities in normal breast cells 175-182

imaging
abstracts 56-58
immunology and immunotherapy
abstracts 116-117

letrozole
combined with antiestrogens in nude mouse model 183-192
loss of heterozygosity (LOH)
of the PTEN region (10q23), correlated with markers of poor prognosis 237-243

male breast cancer
abstracts 52
mammographic parenchymal pattern
unfavorable change associated with risk factors 165-173
mammography
abstracts 56-58
markers
predicting local recurrence after breast-conserving surgery 245-259
see also prognostic factors
markers, circulating
abstracts 121-122
metastasis
to lymph nodes, correlated with LOH of the PTEN region (10q23) 237-243
vasopressin analogue desmopressin inhibits experimental lung metastasis 271-275
metastasis and invasion
abstracts 72-75
micrometastases
abstracts 27,119-121
molecular biology
abstracts 32-33,134-135

nausea
review of 5-HT_3 antagonist antiemetics with breast cancer chemotherapy 207-214

neoadjuvant chemotherapy
abstracts 67-70

oncogenes
abstracts 75-76
ondansetron
review of 5-HT_3 antagonist antiemetics with breast cancer chemotherapy 207-214
outreach
abstracts 45

patient management
abstracts 128-130
percutaneous cryosurgery
abstract 91
phyllodes tumors
histologic factors predicting local recurrence after wide excision 291-295
predictive factors
abstracts 60-65
prevention
abstracts 81-82
procathepsin D
blocking activation peptide of enzymatically inactive procathepsin D inhibits tumor growth 261-269
progesterone receptors
abstracts 95-97
prognosis
adverse markers correlated with LOH of the PTEN region (10q23) 237-243
sentinel node compared with complete axillary dissection 221-229
prognostic factors
abstracts 25-26,98-105
methods — abstracts 41-43
proliferation
low in glycogen-rich breast cancers 215-219
MIB-1 index and likelihood of local recurrence after breast-conserving surgery 245-259
prostate specific antigen (PSA)
from apocrine cells lining breast cysts 157-163
psychosocial aspects
abstracts 130-132

racial aspects
abstracts 46-47
radiation therapy
abstracts 29,107-110
retinoids
tamoxifen/fenretinide therapy inactive in ER– or tam-failing tumors 277-283

risk factors
abstracts 82-84
and unfavorable change in mammographic parenchymal pattern 165-173

San Antonio Breast Cancer Symposium
abstracts 25-139
author index 141-150
program 1-24
screening
abstracts 58-60
sentinel nodes
abstracts 27-28,35-41
compared with complete axillary dissection 221-229
stages of cancer development
abstracts 117-118
surgery
abstracts 110-113

tamoxifen
combined with aromatase inhibitors in nude mouse model 183-192
tamoxifen/fenretinide therapy inactive in ER– or tam-failing tumors 277-283
TGF-β
unchanged by tamoxifen/fenretinide therapy 277-283
tumor biology
abstracts 135-138
tumor suppressor genes
abstracts 75-76

ultrasound, color Doppler
incomplete differentiation of benign and malignant breast lesions 192-199

vasopressin
synthetic analogue desmopressin inhibits experimental lung metastasis 271-275
virology
abstract 139
vomiting
review of 5-HT_3 antagonist antiemetics with breast cancer chemotherapy 207-214

web site
for breast cancer scientific exchange — review 297-298
weight gain
with adjuvant CMF — increased fat mass 285-290